• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eli Lilly (NY:LLY)

    1,137.82 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Sep 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Eli Lilly

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure? ↗
    FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    5 Buy-and-Hold Stocks Built to Weather a Volatile Market ↗
    Ahead of Q4 2026, analysts favor Western Digital, NVIDIA, Vertiv, Eli Lilly, and JPMorgan Chase as steady, best-in-class stocks offering growth with less volatility for buy-and-hold investors. 
    Via MarketBeat
    Topics Artificial Intelligence
    News headline image
    Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗
    The company is still looking to bounce back after the beating it took in recent years. 
    Via The Motley Fool
    Topics Economy
    Eli Lilly (NYSE:LLY) Combines Strong Growth With a Quality Technical Setup ↗
    Via Chartmill
    News headline image
    VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗
    PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything ↗
    The drugmaker has a lot riding on continued clinical progress. 
    Via The Motley Fool
    News headline image
    3 Healthcare Stocks for 3 Stages of Life ↗
    Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends. 
    Via MarketBeat
    News headline image
    3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026 ↗
    These stocks have been struggling lately, but they could be underrated buys in the long run. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets ↗
    Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing... 
    Via MarketBeat
    News headline image
    This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy? ↗
    The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those. 
    Via The Motley Fool
    News headline image
    Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗
    Lilly may be impacted by Novartis' pelacarsen flop -- but not by much. 
    Via The Motley Fool
    News headline image
    State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors ↗
    XLV's 0.08% expense ratio and 22.7% 1-year return outpace IXJ's global reach, but international diversification comes at a cost. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst ↗
    Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind. 
    Via The Motley Fool
    News headline image
    IXJ vs XPH: Global Healthcare ETF or Pharma Focus? ↗
    XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Could This New Opportunity Be Worth Billions for Novo Nordisk? ↗
    The worst may be in the rearview mirror for the drugmaker. 
    Via The Motley Fool
    News headline image
    Amgen Drops 10% on a Trial It Didn't Even Run ↗
    AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact. 
    Via MarketBeat
    News headline image
    Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report ↗
    Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments. 
    Via Benzinga
    News headline image
    These 5 ETFs Are Built for Bear Markets. History Says Now Is a Fantastic Time to Buy. ↗
    During bear markets and recessions, it's good to be invested in "defensive" stocks and funds that hold up better than average. 
    Via The Motley Fool
    Topics ETFs Economy
    News headline image
    Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH ↗
    Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
    Via AB Newswire
    News headline image
    Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? ↗
    One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? ↗
    FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗
    This company aims to serve a market heading toward $100 billion. 
    Via The Motley Fool
    News headline image
    CVS Health Eyes Margin Recovery, Cash Flow as 2027 Headwinds Loom ↗
    CVS Health (NYSE:CVS) executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on... 
    Via MarketBeat
    Topics Earnings
    News headline image
    iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy? ↗
    Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    2025 R&D Spending And Intensity Benchmarks
    Via PRLog
    Topics Supply Chain
    News headline image
    Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031 ↗
    Hint: It's a good idea to buy the stock today. 
    Via The Motley Fool
    News headline image
    Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years ↗
    Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of... 
    Via Benzinga
    News headline image
    Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? ↗
    Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    If I Were in My 20s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever ↗
    Low-cost index funds can be a ticket to prosperity for everyday investors. 
    Via The Motley Fool
    Topics ETFs Economy
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.